ReCode Therapeutics to Participate in February Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)-- ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming February conferences:

William Blair Private Company Focus Conference
Format: Fireside Chat
Date: February 22, 2024
Time: 12:00 p.m. ET
Location: Virtual

Evercore ISI 2024 Emerging Biotech Conference
Format: Company Presentation
Date: February 28, 2024
Time: 4:00 p.m. ET
Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.

ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit www.recodetx.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220712796/en/

Investor Contact:
Anne Marie Fields
Stern IR
[email protected]
[email protected]

Media Contacts:
Erica Jefferson
SVP, Corporate Affairs
ReCode Therapeutics
[email protected]
650-629-7965

Tara Cooper
The Grace Group
[email protected]
650-303-7306

Source: ReCode Therapeutics

You May Also Be Interested In

• HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit
• What Is ORCA? iOrca.xyz Introduces AI Native Prediction Market Infrastructure
• Man Group PLC : Form 8.3 - AMG Critical Materials N.V